Search results for "Pharmacophore"

showing 10 items of 71 documents

3-(2-Fluorophenyl)-6-(phenoxymethyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole

2008

The crystal structure of the title compound, C16H11FN4OS, was synthesized in the course of our studies on 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles as inhibitors of p38 mitogen-activated protein kinase (MAPK). The three-dimensional data obtained were used to generate a three-dimensional pharmacophore model for in silico database screening. The dihedral angles between the central heterocylic system and the fluorophenyl and phenyl rings are 20.21 (3) and 5.43 (1)°, respectively; the dihedral angle between the two benzene rings is 15.80 (4)°.

CrystallographyGeneral ChemistryCrystal structureMeth-Dihedral angleCondensed Matter PhysicsBioinformaticsOrganic PapersMedicinal chemistrychemistry.chemical_compoundchemistryQD901-999DiazoleGeneral Materials SciencePharmacophoreBenzeneActa Crystallographica Section E Structure Reports Online
researchProduct

<strong>In Silico Repurposing, Design, Synthesis and Biological Evaluation of Bisacodyl Analogues</strong>

2018

In a recent article was described in silico repositioning, design, synthesis, biological evaluation and structure-activity relationship (SAR) of an original class of anti-inflammatory agents based on a polyaromatic pharmacophore structurally related to bisacodyl (BSL) drug used in therapeutic as laxative.

Design synthesisComputer scienceIn silicomedicineComputational biologyBisacodylPharmacophoreRepurposingmedicine.drugBiological evaluationProceedings of MOL2NET 2017, International Conference on Multidisciplinary Sciences, 3rd edition
researchProduct

Synthesis of 8-aminomorphans with high KOR affinity

2021

2-Azabicyclo[3.3.1]nonanes (morphans) with a (3,4-dichlorophenyl)acetyl group at 2-position and a pyrrolidino moiety at 8-position were designed as conformationally restricted analogs of piperidine-based KOR agonists. The synthesis started with 4-oxopiperidine-2-carboxylic acid comprising 13 reaction steps. At first the ketone 10 was transformed into diester 7 bearing a propionate side chain. Dieckmann condensation of diester 7 to afford bicyclic enolester 14 and subsequent Krapcho deethoxycarbonylation represent the key steps of the synthesis. The enantiomeric pyrrolidines (1S,5R,8R)-5a and (1R,5S,8S)-5a were separated by chiral HPLC. The eutomer (1S,5R,8R)-5a showed high KOR affinity (K-i…

Diastereoselective reductive aminationEnantiomeric excessStructure-affinity relationshipsPharmacologyPyrrolidinesReceptors Opioid kappaNOESY spectrumOrganic ChemistryMolecular ConformationStereoisomerismGeneral MedicineKOR agonistsEndo-configurationStructure-Activity RelationshipKOR pharmacophoreConformational restrictionChiral HPLCDihedral angleDrug DiscoveryCis/trans-configurationMorphan2-azabicyclo[3.3.1]nonaneEuropean Journal of Medicinal Chemistry
researchProduct

RATIONAL DESIGN AND SYNTHESIS OF NOVEL INHIBITORS OF EPIGENETIC TARGET INVOLVED IN CANCER

2021

Drug DesignKDM4AEpigeneticCarbenoidPCR2Dynamic pharmacophoreSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Design of pharmacophoric group containing 1,4-dihydropyridine derivatives and determination of spectrum of pharmacological activities

2017

Vairākkārtīgi ir uzsvērts, ka 1,4-dihidropiridīna cikls ir viens no farmakoloģiski priviliģētām struktūrām, kas iedarbojas uz jonu kanāliem un dažādiem receptoriem, un kuru modificējot, sintezējot tās struktūras analogus, variējot aizvietotājus molekulā, būtu iespējams iegūt dažādus farmakoloģiski aktīvus savienojumus. Pētījumā ir sintezēti jauni, mērķtiecīgi dizainēti, farmakoforas grupas saturoši 1,4-dihidropiridīna atvasinājumi, sistemātiski mainot farmakoforās grupas (piridīniju un/vai propargil) un to atrašanās vietu molekulā. Izvērtēts sintezēto savienojumu farmakoloģiskās darbības spektrs (aktivitāte uz kalcija kanāliem, antiradikālā aktivitāte un reducējošā kapacitāte), veidots stru…

Farmaceitiskā ķīmijacalcium channel activityPharmacophoreantiradical activitypropargyl grouppyridiniumFarmācijananoparticlesPharmacyReducing capacityPharmaceutical chemistry14-dihydropyridines
researchProduct

Exploring the SARS-CoV-2 Proteome in the Search of Potential Inhibitors via Structure-based Pharmacophore Modeling/Docking Approach

2020

To date, SARS-CoV-2 infectious disease, named COVID-19 by the World Health Organization (WHO) in February 2020, has caused millions of infections and hundreds of thousands of deaths. Despite the scientific community efforts, there are currently no approved therapies for treating this coronavirus infection. The process of new drug development is expensive and time-consuming, so that drug repurposing may be the ideal solution to fight the pandemic. In this paper, we selected the proteins encoded by SARS-CoV-2 and using homology modeling we identified the high-quality model of proteins. A structure-based pharmacophore modeling study was performed to identify the pharmacophore features for each…

General Computer ScienceComputer scienceComputational biologylcsh:QA75.5-76.95Theoretical Computer Science03 medical and health sciences0302 clinical medicineHomology modelingMM-GBSA030304 developmental biology0303 health sciencesVirtual screeningpharmacophoreSARS-CoV-2Applied MathematicsCOVID-19computational chemistryCOVID-19 SARS-CoV-2 computational chemistry structure-based pharmacophore docking MM-GBSADrug repositioningstructure-basedDrug developmentInfectious disease (medical specialty)Docking (molecular)030220 oncology & carcinogenesisModeling and Simulationdockinglcsh:Electronic computers. Computer sciencePharmacophoreDrugBankComputation
researchProduct

Computational methodologies in the discovery of inhibitors of HIV-1

2009

HIV-1 reverse trascriptaseHIV-1 proteasedockingpharmacophore modelingmultivariate analysiSettore CHIM/08 - Chimica FarmaceuticaHIV-1 inhibitor
researchProduct

Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by …

2010

The mdm2 oncogene product, MDM2, is an ubiquitin protein ligase that inhibits the transcriptional activity of the tumor suppressor p53 and promotes its degradation. About 50% of all human cancers present mutations or deletions in the TP53 gene. In the remaining half of all human neoplasias that express the wild-type protein, aberrations of p53 regula- tors, such as MDM2, account for p53 inhibition. For this reason, designing small-molecule inhibitors of the p53-MDM2 protein-protein interaction is a promising strategy for the treatment of cancers retaining wild-type p53. The development of inhibitors has been challenging. Although many small-molecule MDM2 inhibitors have shown potent in vitr…

IndolesTumor suppressor geneAntineoplastic AgentsMolecular Dynamics SimulationBioinformaticsBiochemistryGene productNeoplasmsDrug DiscoverymedicineHumansImidazolinesMolecular Modeling New Drugs for Anti-Cancer Therapy p53-MDM2 InteractionPharmacologyBenzodiazepinonesbiologyOncogeneOrganic ChemistryCancerProto-Oncogene Proteins c-mdm2medicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaSmall moleculeUbiquitin ligaseOxindolesProtein Structure TertiaryDrug Designbiology.proteinCancer researchMolecular MedicineMdm2PharmacophoreTumor Suppressor Protein p53Current medicinal chemistry
researchProduct

The Molecular dYnamics SHAred PharmacophorE (MYSHAPE) approacha new tool to arise docking and pharmacophore modeling performance: virtues and vices

2017

In a recent paper, we presented a new virtual screening workflow that addresses the arising issues of molecular docking and pharmacophore modeling when using a single set of coordinates and a single active ligand [1]. MD simulations were carried out and ligand-protein interactions were analyzed and collected together with their appearance frequency. A pharmacophore model was then created using only the common feature patterns that all the ligands exhibited during MD simulations. This ‘Molecular dYnamics SHAred PharmacophorE’ was then used for virtual screening on active and inactive molecules library. MYSHAPE was also used as constraints for the creation of the docking grid. The application…

MYSHAPE Pharmacophore
researchProduct

N-valproyl-L-tryptophan for CNS-targeting: synthesis, characterization and efficacy in vitro studies of a new potential antiepileptic drug.

2010

A new aminoacidic derivative of valproic acid (VPA) has been synthesized and characterized by analytical and spectral data. The rationale for the preparation of such potential antiepileptic agent is based on the observation that chemical combination of the anticonvulsant pharmacophore, VPA with essential aminoacids could afford more effective and less toxic actives. The synthesis, characterization, physico-chemical parameters functional for crossing Blood Brain Barrier of N-valproyl-L-tryptophan (4) are reported. The Log D pH7.4 (0.3) indicates that (4) is adequate to cross biological membranes. Its chemical and enzymatic stability were assessed. The experiments indicate high stability of c…

Malemedicine.medical_treatmentHippocampal formationPharmacologyIn Vitro TechniquesBlood–brain barrierSettore BIO/09 - FisiologiaHippocampuschemistry.chemical_compoundDrug StabilityIn vivoDrug DiscoverymedicineAnimalsRats WistarValproic AcidEpilepsyDipeptidesAminoacidic derivative Antiepileptic Drug CNS-Targeting Enzymatic Stability Seizure Like Events Model Valproic acidIn vitroElectrophysiological PhenomenaRatsmedicine.anatomical_structureAnticonvulsantchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAnticonvulsantsPharmacophoreDerivative (chemistry)medicine.drugMedicinal chemistry (Shariqah (United Arab Emirates))
researchProduct